Aurobindo Pharma Ltd. Hits Intraday Low Amid Price Pressure on 10 Feb 2026

Intraday Performance and Price Movement

The stock of Aurobindo Pharma Ltd., a key player in the Pharmaceuticals & Biotechnology sector, underperformed significantly during the trading session. It recorded a day change of -5.07%, marking a reversal after two consecutive days of gains. The intraday low of Rs 1,142.8 represents a 4.87% drop from its previous close, signalling a sharp pullback within the session.

This decline contrasts sharply with the broader market trend, where the Sensex opened 144.25 points higher and maintained a positive trajectory, trading at 84,340.25 points, up 0.33%. The Sensex is currently just 2.16% shy of its 52-week high of 86,159.02, supported by mega-cap stocks leading the gains.

Technical Indicators and Moving Averages

From a technical standpoint, Aurobindo Pharma is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This positioning indicates a bearish short- to medium-term trend, with the stock facing resistance at multiple technical levels. The failure to hold above these averages adds to the selling pressure observed during the day.

The stock’s Mojo Score currently stands at 68.0, with a Mojo Grade of Hold, reflecting a recent downgrade from Buy on 1 Dec 2025. This shift in grading may have contributed to cautious sentiment among traders, influencing the intraday price weakness.

Comparative Sector and Market Performance

In comparison to its sector and the broader market, Aurobindo Pharma’s performance today was notably weaker. The stock underperformed its Pharmaceuticals & Biotechnology sector by 4.84%, while the Sensex posted a positive gain of 0.33%. Over the past week, the stock has declined by 7.01%, whereas the Sensex has risen by 0.72%. Similarly, the one-month performance shows a 4.87% drop for Aurobindo Pharma against a 0.91% gain for the Sensex.

Longer-term trends also highlight a divergence from the benchmark index. Over the past year, Aurobindo Pharma has declined by 3.14%, while the Sensex has advanced by 9.09%. Year-to-date, the stock is down 3.48%, compared to the Sensex’s 1.03% decline. Despite these recent setbacks, the stock has delivered a 143.21% gain over three years, outperforming the Sensex’s 38.99% rise in the same period.

Market Sentiment and Immediate Pressures

The intraday weakness in Aurobindo Pharma appears to be driven by a combination of technical selling and cautious sentiment following the downgrade in its Mojo Grade. The stock’s inability to sustain gains after two positive sessions suggests that traders are taking profits or responding to the shift in outlook. Additionally, the broader market’s focus on mega-cap stocks and the Sensex’s steady climb may have diverted attention and capital away from mid-cap pharmaceutical stocks like Aurobindo Pharma.

Despite the overall positive market environment, the stock’s trading below all major moving averages signals that immediate price pressures remain. This technical backdrop, coupled with the recent downgrade, has contributed to the stock hitting its intraday low and underperforming relative to its sector and the benchmark index.

Summary of Key Metrics

Aurobindo Pharma’s market capitalisation grade is 2, reflecting its mid-cap status within the Pharmaceuticals & Biotechnology sector. The stock’s recent downgrade from Buy to Hold on 1 Dec 2025 aligns with its current underperformance and technical challenges. The Mojo Score of 68.0 indicates a moderate outlook, with the stock facing headwinds in the near term.

While the Sensex continues its three-week consecutive rise, gaining 3.44% in that period, Aurobindo Pharma’s relative weakness highlights the divergence between large-cap market leaders and mid-cap pharmaceutical stocks. The stock’s performance today, with a 5.09% decline against the Sensex’s 0.33% gain, underscores the immediate price pressure and cautious market sentiment surrounding it.

Conclusion

On 10 Feb 2026, Aurobindo Pharma Ltd. encountered significant intraday selling pressure, resulting in the stock touching a low of Rs 1,142.8 and declining over 5% during the session. This movement occurred despite a broadly positive market environment, with the Sensex advancing and trading near its yearly highs. The stock’s position below all major moving averages and its recent downgrade to a Hold rating have contributed to the subdued sentiment and price weakness. Investors and market participants will be closely monitoring the stock’s ability to regain technical support levels amid ongoing sector and market dynamics.

Unlock special upgrade rates for a limited period. Start Saving Now →